Galcanezumab

Galcanezumab (INN) is a humanized monoclonal antibody designed for the prevention of migraine.^[1]^[2]

This drug was developed by Eli Lilly & Co.

References

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab

Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡

Chimeric ("-cixi-")	Abciximab Volociximab

Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab Atinumab Erenumab Fasinumab Fulranumab Gantenerumab Opicinumab

Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab

Humanized ("-anibizu-")	Ranibizumab

Human ("-gru-")	Bimagrumab

Humanized ("-grozu-")	Domagrozumab Landogrozumab

This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.